Pharmaceuticals
Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China
The Company is working closely with its commercial partners to supply the combination therapy to patients in need Brii Bio progressed the combination therapy from discovery to global Phase 3 data readout and first regulatory approval by the China NMPA in less than 20 months, validating the Com...
2022-07-07 07:10
5152
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, July 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first patient has bee...
2022-07-06 23:00
3115
I-Mab to Host 2022 R&D Day
GAITHERSBURG, MD. and SHANGHAI, July 6, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it will host its 2022 Research and Devel...
2022-07-06 20:00
2248
US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
SYDNEY, July 6, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia's paxalisib for t...
2022-07-06 19:00
4080
Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China
Collaboration will provide biopharmaceutical companies access to Guardant Health's broad portfolio of cancer tests to help advance drug development programs and their clinical trials SINGAPORE, July 6, 2022 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company,...
2022-07-06 18:17
5555
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007
SAN DIEGO and HONG KONG and SYDNEY, July 6, 2022 /PRNewswire/ -- Inmagene
Biopharmaceuticals ("Inmagene
2022-07-06 12:00
2370
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
-- ASC10 is an oral small molecule drug candidate, which is in-house discovered and developed, and Ascletis retains full global rights for its development and commercialization --This IND filing of ASC10 in the U.S. will accelerate Ascletis' global multi-center clinical studies on ASC10 and bett...
2022-07-06 08:10
4956
Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17
* Nuvaxovid™ COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 inEurope GAITHERSBURG, Md., July 5, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious inf...
2022-07-05 23:37
4679
EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement
FUKUOKA, Japan, July 5, 2022 /PRNewswire/ -- EditForce, Inc. (Headquarters: Fukuoka, President and CEO: Takashi Ono; hereinafter "EditForce") has entered into a License Agreement (hereinafter "Agreement") with Mitsubishi Tanabe Pharma Corporation (Headquarters:Osaka, Representative Director: Hiro...
2022-07-05 15:00
2541
Endurance RP Limited (SEHK:0575.HK) Operational Update on the PE Prevention Drug Fortacin™ / Senstend™
Phase 3 Study in China is Estimated to Complete in November 2022 HONG KONG, July 5, 2022 /PRNewswire/ -- Endurance RP Limited ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) is pleased to provide updates on the PE prevention drug - Fo...
2022-07-05 12:06
4228
ClinChoice Raises $150 mm Series E Round Financing, Further Strengthening its Global Services Capabilities
PHILADELPHIA, July 4, 2022 /PRNewswire/ -- Recently, ClinChoice announced the successful completion of its $150 mm Series E round financing. The investment was led by Legend Capital, and co-invested by Taikang Life Insurance, Sherpa Healthcare Partners and existing shareholders, including Lilly A...
2022-07-05 09:20
3022
Arctic Vision Announces First Patient Enrolled in Phase III Clinical Trial of ARVN003 for Presbyopia
This is the first clinical trial approved in China for presbyopia drugs and Arctic Vision's study marks the first patient enrollment in a Phase III clinical trial for presbyopia drugs inChina. ARVN003 is expected to be the first approved drug for presbyopia inChina. SHANGHAI, July 4, 2022 /PRNew...
2022-07-04 22:14
3144
JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma
SHANGHAI, July 4, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of phase I clinical study of JWATM204 in patients with advanced ...
2022-07-04 19:30
5851
Octapharma shares new data at ISTH 2022 in its mission to meet the challenges faced by people with bleeding disorders
LACHEN, Switzerland, July 4, 2022 /PRNewswire/ -- * Octapharma to present new clinical and scientific data from across Octapharma's haematology and critical care portfolios during the ISTH 2022 Congress * Data to be presented in 11 poster presentations and during two Supported Symposia * N...
2022-07-04 18:00
4021
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061
SHANGHAI, July 4, 2022 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256.HK, referred to "Abbisko Therapeutics" hereafter) today announced completion of dosing of the first patient in the Phase 1 clinical trial in advanced solid tumors for ABSK061, which becomes the first high...
2022-07-04 13:34
3096
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
HANGZHOU and SHAOXING, China, July 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the clinical study of PD-L1 antibody ASC22 in combination with Chidamide for functional cure of human immunodeficiency virus (HIV) infection, which was initiated by Shangh...
2022-07-04 08:10
3770
Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis
SAN FRANCISCO and SUZHOU, China, July 4, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and ot...
2022-07-04 08:00
4083
Brii Biosciences Exercises Option for Vir Biotechnology's VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China
Exclusive development and commercialization rights to VIR-3434 in China strengthen Company's leadership and robust clinical pipeline in HBV Key partnership with Vir enables multitude of combination treatment options as part of Company's strategic approach to developing a functional cure for HBV ...
2022-07-04 07:10
4576
ReviR Therapeutics Appoints Paul August, Ph.D., as Chief Scientific Officer
SOUTH SAN FRANCISCO, Calif., July 1, 2022 /PRNewswire/ -- ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced the appointment ofPaul August, Ph.D., as the Chief Scientific Officer. "We are thrilled to welcome Dr. August to our team," s...
2022-07-01 22:00
5587
GSK Spreads Awareness on Vaccine-Preventable Diseases, Attempting to Bridge the Vaccination Gap in Malaysia
Building public trust and educating on the importance of getting vaccinated KUALA LUMPUR, Malaysia, July 1, 2022 /PRNewswire/ -- GSK is a science-led global healthcare company, delivering vaccines that help protect people at all stages of life. GSK's new purpose is to unite science, technology an...
2022-07-01 09:16
3676
Week's Top Stories
Most Reposted
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 313 media titles]
2026-08-07 22:30Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
[Picked up by 301 media titles]
2026-08-06 15:10
GCash Parent Mynt Cited as Sole Philippine Firm in World's Top Fintech Companies List
[Picked up by 295 media titles]
2026-08-12 16:02
MetaOptics Ltd achieves 79% of FY2025 full-year revenue in 1H 2026, on track to fulfil purchase orders of key metalens production equipment in 2H 2026
[Picked up by 293 media titles]
2026-08-11 19:03Two CityUHK scholars elected to the European Academy of Engineering in recognition of their internationally acclaimed research achievements
[Picked up by 291 media titles]
2026-08-10 19:12
Most Read
Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
2026-08-06 15:10
16243
AMTD IDEA's Receipt of NYSE Letter Regarding ADS Trading Price's Below Compliance Standards
2026-08-08 04:01
10080
China Yuchai International Announces Unaudited 2026 First Half-Year Financial Results
2026-08-07 18:00
9953